HDFC MF and ADIA Lead ₹777 Crore Block Deal in Corona Remedies
A significant shift in the shareholding pattern of pharmaceutical player Corona Remedies Limited took place on June 17, 2026, as major institutional investors moved to acquire substantial stakes. The massive block deal saw marquee names like HDFC Mutual Fund and the Abu Dhabi Investment Authority (ADIA) entering the fray, signaling strong institutional confidence in the company.
Massive Divestment by Sepia Investments and Anchor Partners
The block deal was primarily driven by the exit of two major sellers. Sepia Investments offloaded 43,28,943 shares of Corona Remedies at a price of ₹1,730 per share, amounting to a deal value of approximately ₹748.9 crore. Adding to this volume, Anchor Partners divested 1,61,861 shares at the same price, contributing another ₹28 crore to the transaction. Combined, these two entities offloaded shares worth roughly ₹776.9 crore in the pharmaceutical company.
HDFC Mutual Fund Dominates the Buy Side
The absorption of these shares was led by a diverse group of twelve institutional investors. HDFC Mutual Fund emerged as the most aggressive buyer, acquiring 24,50,000 shares worth approximately ₹423.9 crore. This single transaction accounted for more than half of the total deal value, underscoring HDFC MF's significant conviction in the stock's future prospects.
Other prominent domestic and international players also participated heavily:
- Aditya Birla Sun Life Mutual Fund acquired 4,90,000 shares worth ₹84.8 crore.
- Invesco Mutual Fund picked up 2,89,017 shares, valued at around ₹50 crore.
- Kotak Mahindra Mutual Fund bought 1,61,861 shares, matching the exact quantity sold by Anchor Partners, worth ₹28 crore.
Global Institutional Interest in Corona Remedies
The deal also highlighted significant interest from global fund managers and sovereign wealth funds. Aberdeen Asian Smaller Companies Investment Trust Plc purchased 4,50,868 shares for approximately ₹78 crore, while the Aberdeen Standard Sicav I - Asian Smaller Companies Fund took up 2,74,132 shares worth ₹47.4 crore.
또한, 아부다비 투자청(ADIA)은 6,800만 루피 상당의 주식 39,130주를 매입하며 캡 테이블(cap table)에 합류했습니다. 다른 해외 참여자로는 2억 5,100만 루피를 투자한 WhiteOak Capital Mutual Fund와 2억 5,700만 루피 상당의 주식을 매입한 India Acorn ICAV - Ashoka WhiteOak Emerging Markets Equity Fund가 있습니다. Factory Mutual Insurance Company와 같은 소규모 니치 플레이어들도 참여하여 1,900만 루피 상당의 주식 10,670주를 확보했습니다.
핵심 요약
- 주요 기관 매각: Sepia Investments와 Anchor Partners는 Corona Remedies에서 총 약 77억 6,900만 루피 규모의 지분을 매각했습니다.
- HDFC MF의 매수 주도: HDFC Mutual Fund가 주요 매수자로 나서 전체 거래 가치의 50% 이상을 차지하는 42억 3,900만 루피 상당의 주식을 매입했습니다.
- 높은 기관 신뢰도: ADIA 및 다양한 Aberdeen 펀드와 같은 글로벌 기관들의 참여는 제약 부문에 대한 강력한 국경 간 기관 투자 관심을 시사합니다.